

Joint INTERCOUNTRY WORKSHOP on  
**Crimean-Congo Haemorrhagic Fever (CCHF) Prevention and Control**  
(Which strategies for the control of future outbreaks?)

Istanbul, Turkey, 6-8 November 2006

**ORGANIZING INSTITUTIONS:** World Health Organization (MZCP<sup>1</sup>-EMRO<sup>2</sup>-EURO<sup>3</sup>-HQ<sup>4</sup>) in collaboration with the WOAHOIE<sup>5</sup>, the FAO/UN<sup>6</sup> and the ICTTD<sup>7</sup>

**Purposes and Objectives**

General Objective

- To discuss the lessons learnt during last outbreak of CCHF and prepare guidelines to more efficiently respond during future VHF outbreaks notably regarding case management and social mobilization issues.

Specific Objectives

1. Review of the CCHF situation (epidemiology, laboratory diagnosis and the public health importance) in the European belt (WHO/EURO), the South Mediterranean and the Middle East regions (WHO/EMRO);
2. Review the CCHF clinic, the case management and infection control in hospital settings;
3. Understand the role and contribution of public health awareness, community participation and intersectoral effectiveness;
4. Review knowledge on ticks ecology and possible forecasting models for CCHF;
5. Develop coordinated regional and national multisectoral plans for integrated prevention and control of CCHF and control of risks-vectors of the disease.

## *Provisional Programme*

### MONDAY, 6 NOVEMBER

08:15 - **Welcoming remarks and presentation of the Workshop**

- ARISTARCHOS SEIMENIS, WHO/MZCC, Athens, Greece
- HASSAN EL BUSHRA, WHO/EMRO, Cairo, Egypt
- ROBERTA ANDRAGHETTI on behalf of BERNARDUS GANTER, WHO/EURO, Copenhagen, Denmark
- Representatives of Their Excellencies the Ministers of Health and Agriculture, Turkey

### **Session 1. Outbreak Response: field epidemiology, prevention, surveillance and control**

Chairpersons: ROBERTA ANDRAGHETTI on behalf of BERNARDUS GANTER, B. SWANEPOEL

08:30 - *Surveillance and control of CCHF outbreaks worldwide*

**PIERRE FORMENTY**, CDS/EPR, WHO-HQ

08:45 - *Surveillance of VHF in EURO and EMRO regions: regional perspective*

**ROBERTA ANDRAGHETTI** on behalf of **BERNARDUS GANTER**, EURO and **HASSAN EL BUSHRA**, EMRO

09:00 - *Epidemiology, Surveillance and Control of CCHF in Kosovo*

**ISUF DEDUSHAJ** and **ISME HUMOLLI**, National Institute of Public Health of Kosovo, Pristina, Kosovo

09:15 - *Epidemiology, Surveillance and Control of CCHF in Pakistan*

**SYED SOHAIL ZAHOOR ZAIDI**, National Institute of Health, Islamabad, Pakistan

09:45 - 10:15 *Coffee-Tea Break*

10:15 - *Surveillance and Control of CCHF in Iran.*

**SADEGH CHINIKAR**, Institute Pasteur, Teheran, Iran

1 WHO/Mediterranean Zoonoses Control Programme, Athens, Greece

2 WHO/Eastern Mediterranean Regional Office, Cairo, Egypt

3 WHO/European Regional Office, Copenhagen, Denmark

4 WHO/Headquarters, Epidemic and Pandemic Alert and Response Department, Geneva, Switzerland

5 World Organization for Animal Health (OIE), Paris and Beirut

6 Food and Agriculture Organization/UN, Rome, Italy

7 Integrated Consortium on Ticks and Tick-borne Diseases, Utrecht, The Netherlands

- 10:30 - *Surveillance and Control of CCHF in China.*  
**LI DEXIN**, China CDC, Beijing, China
- 10:45 - *Surveillance and Control of CCHF in Bulgaria.*  
**WILLIAM MONEV**, Sofia, Bulgaria
- 11:00 - *Surveillance and Control of CCHF in Turkey.*  
**RAMAZAN UZUN**, MoH, Ankara, Turkey
- 11:15 - *Crimean Congo Haemorrhagic Fever - criteria for being an OIE listed disease.*  
**DEMPSEY H. DE LANGE**, World Organization for Animal Health-OIE, Paris, France.

## **Session 2. Laboratory diagnosis: from the field to the P3-P4**

Chairpersons: **S. CHINIKAR**, **T. ASVIC**,

- 11:30 - *The current laboratory diagnosis techniques for CCHF: collection of samples, shipment of samples, biosafety considerations, analysis and its interpretation.*  
**STEPHAN GÜNTHER**, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- 11:45 - *CCHF field laboratory during outbreaks: do we have a test for bedside diagnosis ?*  
**HEINZ FELDMANN**, Special Pathogens Program, Health Canada, Canada.
- 12:00 - *Analysis of the national and regional strategies for the CCHF laboratory diagnosis within EURO: what are the needs and where is the expertise.*  
**MATHIAS NIEDRIG**, European Network for Viral Imported Diseases, Berlin, Germany
- 12:15 - *Analysis of the national and regional capacities for the CCHF laboratory diagnosis within EMRO*  
**MARSHALL MONTEVILLE and KEN EARHART**, NAMRU-3, Cairo, Egypt.

12:30 - 14:00 LUNCH

14:00 - 16:00 *Discussion in plenary and recommendations for Session 1*

- Objectives:
- case definition for CCHF surveillance: a syndrome approach
  - case definition for CCHF during outbreaks
  - consensus on a general strategy for outbreak response and control
  - improving the country transparent reporting of CCHF cases in the framework of the new International Health Regulations

16:00 - 16:30 Coffee-Tea Break

16:30 - 17:30 *Discussion in plenary and recommendations for Session 2*

- Objectives:
- The need for bedside diagnosis: a need for laboratory confirmation for Ribavirin treatment ?
  - Lab results should be included in the case definition ?
  - Decision tree for lab confirmation in the field ?
  - Practical field problems in collecting biological specimens, packaging and shipments from the field to nearest competent laboratory.
  - Facilitating shipment of biological specimens across borders to globally recognized laboratories
  - Distribution of all contact numbers of reference laboratories
  - Support establishment of Regional reference laboratories.
  - CCHF lab diagnosis: a national or a regional strategy ?

## **TUESDAY, 7 NOVEMBER**

### **Session 3. Clinical management and infection control for CCHF patients**

Chairpersons: **I. DEDUSHAJ**, **N. SHEIKH**, **O. ERGONUL**,

- 08:00 - *Risk factors and prevention strategy of CCHF in South Africa.*  
**BOB. SWANEPOEL**, NICD, South Africa
- 08:30 - *Recommended standard infection control practices during CCHF outbreaks*  
**GLENN SCHNEPF**, WHO-HQ, CDS/EPR, Geneva, Switzerland

09:00 - *Recommended infection control practices during CCHF outbreaks in high technology settings: example of recently imported CCHF cases in France and Germany*  
**ARNAUD TARANTOLA**, Institut de Veille Sanitaire, Paris, France

09:20 - *Current review of CCHF clinical description*,  
**SALIAHMETI**, University Hospital, Pristina, Kosovo

09:40 - *Current review of CCHF case management and treatment*  
**NAZIF ELALDI**, MoH, Ankara, Turkey

10:15 - *Ribavirin use during treatment of CCHF infection: triage, dosage and side effects*.  
**HALUK VAHABOGLU**, Ankara, Turkey

10:00 - 10:30 Coffee-Tea Break

10:50 - *Immune and physiological human responses to CCHF infections and factors influencing the outcome in patients*  
**ZULAL OZKURT**, Ataturk University, Medical Faculty, Erzurum, Turkey

11:10 - *MSF operational response to Viral haemorrhagic fevers in EURO and EMRO*  
**MARTIN DE SMET**, Médecins-Sans-Frontières, Belgium

12:15 - 14:00 LUNCH

14:00-17:00 *Discussion in plenary session and recommendations*

16:00 - 16:15 Coffee-Tea Break

Objectives:

- Discuss the writing of field guidelines for CCHF clinical diagnostic
- Ribavirin treatment guidelines (doses, formulation, disease, timing),
- Ribavirine: need for clinical trials ? Oral ribavirine versus IV ribavirine ?
- Ribavirine for post-exposure treatment ?
- CCHF infection control guidelines in low and high technology settings
- Is there a need for new treatments or new vaccines ?
- Guidelines for burials of patients infected with CCHF.
- Promoting research activities in affected countries.

## WEDNESDAY, 8 NOVEMBER 2006

### **Session 4.** *Social mobilization and health education: is prevention effective?*

Chairpersons: **P. FORMENTY, H. EL BUSHRA, S. RANDOLPH**

08:00 - *Communication strategy during the last CCHF outbreaks in Pakistan. KAP studies ?*  
**NADEEM SHEIKH**, Bolan Medical College, Quetta, Pakistan

08:40 - *Risk factors studies and prevention strategy of CCHF in Iran*.  
**SHAHROKH IZADI**, MoH, Teheran, Iran

09:10 - *Risk factors and prevention strategy of CCHF in Albania*.  
**S. BINA**, National Institute of Public Health, Tirana Albania

09:40 - *Risk factors and prevention strategy of CCHF in Turkey*.  
**LEVENT AKIN**, MoH, Ankara, Turkey

10:00 - 10:30 Coffee-Tea Break

10:30 - *What are the key messages for CCHF prevention and how to make them understood by the population: a COMBI approach*.  
**RAIL SUHAILI**, WHO Mediterranean Centre for Vulnerability Reduction, Tunis, Tunisia.

10:50-12:30 *Discussion in plenary session and recommendations*.

Objectives:

- Management of tick bite (or tick-human contact) through social mobilization
- Limit tick population through social mobilization
- Prevention: what should be the key message regarding tick bite, home care, safe injection, hospitalization and funerals ?

12:15 - 14:00 LUNCH

## **Session 5. CCHF virus and ticks, population models and climate change**

Chairpersons: **F. JONGEJAN**, **ZATI VATANSEVEN**

**14:00** - *Epidemiology studies in South Africa.*

**BOB SWANEPOEL**, NICD, Johannesburg, South Africa

**14:20** - *CCHF virus and its ticks worldwide*

**FRANS JONGEJAN**, University of Pretoria, ICTTD, Pretoria, South Africa and  
**ZATI VATANSEVEN**, University of Ankara, Ankara, Turkey

**14:40** - *A forecasting model for Rift valley fever and other arboviruses in Africa: can a prediction tool help public health decision-makers ?*

**ASSAF ANYAMBA**, NASA/ Goddard Space Flight Center, Biospheric Sciences Branch, USA

**15:00** - Predictive mapping applied to CCHF

**AGUSTIN ESTRADA-PENA**, University of Zaragoza, Zaragoza, Spain

**15:20** - *Environmental patterns and forecasting model for tick-born encephalitis: can we apply it to CCHF and Hyalomma ?*

**SARAH RANDOLPH**, Oxford University, Oxford, United Kingdom

**15:40-16:40** *Discussion in plenary session and recommendations*

- Objectives:
- Testing predictive models will need intense collaboration between key countries and model makers
  - What should be the strategy to "control" tick populations ?  
Is a coordinate approach Pesticides + Social mobilization enough ?

**16:40 - 17:00: Break**

**17:00-18:00** **Critical review of the recommendations and conclusion of the workshop**

